-
COMPEL Data Show Osimertinib Plus Chemo Beats Chemo Alone for EGFRm NSCLC Following Progression
While ultimately underpowered, Dr. Giulia Pasello said combination therapy demonstrated an improvement in median PFS compared to chemotherapy alone.
More News from #WCLC25
-
Test Your Knowledge at the Closing Lunch of the 2025 World Conference on Lung Cancer
Before you depart Barcelona, join your colleagues for lunch and an entertaining trivia competition, hosted by quizmaster Stephen Liu, MD.
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.